10-Q quarterly report · filed Nov 13, 2026

ACTUATE THERAPEUTICS, INC. (ACTU) Q3 2026 10-Q Quarterly Report

Short answer

ACTUATE THERAPEUTICS, INC. (ACTU) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$3M
+36.7% YoY · +29.7% QoQ
EPS (diluted)
−$0.14
+44.0% YoY · +30.0% QoQ

Source: XBRL data from the ACTUATE THERAPEUTICS, INC. (ACTU) Q3 2026 10-Q on SEC EDGAR. USD.

ACTUATE THERAPEUTICS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales generated
  • Operating margin not applicable, operating loss $3,439,087 vs $5,472,378 YoY
  • Worst expense category: R&D $1,811,601 vs $2,177,922, down $366,321
  • Cash $2,101,816; operating cash use $12,373,256 for nine months
  • October offering net proceeds $11,764,494; substantial doubt regarding going-concern status and additional funding needs

Risk Factors

  • No material changes identified in the 10-Q Risk Factors section versus the 2025 10-K
  • Liquidity risk: cash $2,101,816 and working-capital deficit $974,694, with substantial doubt about going-concern status
  • Capital-markets risk: funding needs persist despite $11,764,494 October offering net proceeds
  • Nasdaq compliance risk: noncompliance with $50 million MVLS and $1.00 minimum-bid requirements
  • Clinical-development risk: elraglusib advancement depends on FDA or EMA feedback and patient enrollment

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ACTUATE THERAPEUTICS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.